Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Kanegafuchi Kagaku Kogyo Kabushiki Kaisha

Other

Bristol-Myers Company

Taiho Pharmaceutical Company Limited

Taisho Pharmaceutical Co., Ltd.

Banyu Pharmaceutical Co. Ltd

Kanegafuchi Chemical Industry Co., Ltd.

Microbial Chemistry Research Foundation

Mercian Corporation

501 Azidan Hojin Biseibutsu Kagaku Kenkyu Kai

Zaidin Hojin Biseibutsu Kagaku Kenky Kai

Masaaki Ishizuka

Tomio Takeuchi

Hamao Umezawa

Masa Hamada

Hiroshi Naganawa

Takaaki Aoyagi

Toshikazu Oki

Kenji Maeda

Taiji Inui

Shinichi Kondo

Kunio Isshiki

Hironobu Iinuma

Hiroyuki Kumagai

Akio Fujii

Teruya Nakamura

Tetsushi Saino

Yoshihide Fuse

Hajime Morishima

Fuminori Abe

Ikuo Matsumoto

Tadayoshi Shiraishi

Takashi Terada

Hamao Umezawa, Deceased

Norio Shibamoto

Takuzo Yamamoto

Terukatsu Sakurai

Toshiaki Katsumi

Masaji Kawazu

Atsushi Takahashi

Donald W Kufe

Kiyoshi Watanabe

Masakazu Fukushima

Takeo Yoshioka

Ralph R Weichselbaum

Takayoshi Hidaka

Nobuyoshi Shimada

Tomohisa Takita

Yoshiro Okami

Akira Takamatsu

Tsutomu Sawa

Hiroshi Tone

Hiroyuki Inoue

Naoto Kawamura

Junji Yoshizawa

Tomohiro Sameshima

Tetsuya Someno

Masaaki Hosoi

Naoki Agata

Motoko Matsufuji

Toshiaki Yamashita

Kuniki Kato

Takashi Yamashita

Corinne L Reimer

Mitsuhiro Ueno

Toshiyuki Toko

Noriyuki Naoi

Toshiyuki Kamayama

Shogo Kurasawa

A compound represented by formula (I); a process for producing a compound (substance F-1490) of formula (I), wherein X represents &#x2014;O&#x2014; and R represents a hydroxyl group, by using a microorganism belonging to the genus; and asp. F-1490 strain (FERM BP-8287) capable of producing the substance F-1490; and an osteoclast differentiation inhibitory agent containing as an active ingredient the compound represented by formula (I): wherein X represents &#x2014;O&#x2014; or &#x2014;CH&#x2014;, and R represents a hydroxyl group when X represents &#x2014;O&#x2014;, or a hydrogen atom when X represents &#x2014;CH&#x2014;.

Osteoclast differentiation inhibitors

A method for enhancing the efficacy of chemotherapy and/or radiation in the treatment of cancer in animals, particularly humans, is provided wherein certain isocoumarin derivatives which exhibit unique radiosensitization activity and/or chemopotentiation properties are employed in a combination treatment with ionizing radiation and/or chemotherapy.

Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives

A novel amino acid derivative represented by the general formula (I) shown below or a salt thereof have now been provided by chemical synthesis, and it has been found that these new compounds stimulate proliferation and physiological activities of the T cells of mammals, have an immunomodulating activity and also have an antitumor activity or a carcinostatic activity. It has also been found that these new compounds have an effect of stimulating the proliferation of hematopoietic stem cells.

Amino acid derivatives

Preventives and remedies for ulcerous colitis and/or crohn's disease

Method for treating diarrhea

A novel amino acid derivative represented by the general formula (I) shown below or a salt thereof have now been provided by chemical synthesis, and it has been found that these new compounds stimulate proliferation and physiological activities of the T cells of mammals, have an immunomodulating activity and also have an antitumor activity or a carcinostatic activity. It has also been found that these new compounds have an effect of stimulating the proliferation of hematopoietic stem cells. ##STR1## wherein y is 0 or 1; R.sup.1 represents an unsubstituted C.sub.1 -C.sub.8 alkyl group or others;

Antibiotics having immunosuppressive activity, delaminomycins and

A new antibiotic, named Conagenin, is provided which can exhibit useful carcinostatic or antitumor activities on carcinomas and tumors, particularly malignant tumors, of mammalian animals including man. Conagenin can be produced by fermentation of microorganisms of genus Streptomyces, typically Streptomyces roseosporus MI696-AF3 strain identified under the deposit number FERM BP-2738. Conagenin has formula (I) and is useful for medicinal purposes, particularly as carcinostatic agent or antitumor agent for inhibiting carcinomas and malignant tumors of mammalian animals, including man.

Carcinostatic or antitumor antibiotic, conagenin, and production and

As a new antibiotic is provided a compound, now nominated as MI43-37F11 substance, which has formula ##STR1## This MI43-37F11 substance has an antitumor activity, an activity to enhance the production of interleukin-1 in vivo in a mammalian, and an activity to activate a macrophage in vivo in a mammalian. MI43-37F11 substance may be produced by cultivation of Streptoverticillium eurocidicum MI43-37F11 strain identified as FERM BP-2783.

Anticancer antibiotic MI43-37F11 substance

A novel compound having anti-tumor activity is disclosed which is 1,12-dihydroxy-1,6,12,17-tetraazacyclodocosan-2,5,13,16-tetrone produced microbiologically by culturing a microorganism belonging to the genus of Alteromonas or, in particular, Alteromonas haloplanktis SB-1123. The characterization data of the compound and the microbiological properties of the microorganism are described. The results of in vitro assays are given for the anti-tumor activity of the compound against L-1210 and IMC carcinoma cells.

Bisucaberin

New physiologically active substances, arphamenine A and arphamenine B which are generically termed arphamenine are produced from a new microorganism, BMG361-CF4 strain identified as FERM P-6521 or FERM BP-286 or ATCC No. 39373. Arphamenine is useful as a host defence stimulator having an activity to enhance cell-mediated immunity, and also as an anti-tumor agent.

New physiologically active substance, arphamenine and production thereof

The present invention relates to an immunosuppressing method which comprises administering a spergualin-related compound represented by the following formula ##STR1## (wherein R.sub.1 is --(CH.sub.2).sub.4 --, --(CH.sub.2).sub.6 --, ##STR2## R.sub.2 is --(CH.sub.2).sub.2 -- or --CH.dbd.CH--; and R.sub.3 is ##STR3## or pharmacologically acceptable salts thereof in an effective amount to a warm-blood animal.

Immunosuppressing method

A stable, non-hygroscopic, crystalline .gamma.-form of bestatin is prepared from the .alpha.- or .beta.-form of bestatin by heating at a temperature of from about 148.degree. C. to the melting point of bestatin, or by suspending or kneading in certan specified solvents.

Crystalline upsilon-form bestatin and processes for its preparation

This invention relates to method for suppressing a transplantation immunity and treating an allergic disease and an autoimmune disease in a mammal which comprises administering spergualin or a pharmaceutically acceptable salt thereof in effective amount to the said mammal.

Method for suppressing a transplantation immunity and treating an

A stable, non-hygroscopic, crystalline .gamma.-form of bestatin is prepared from the .alpha.- or .beta.-form of bestatin by heating at a temperature of from about 148.degree. C. to the melting point of bestatin, or by suspending or kneading in certain specified solvents.

Crystalline gamma-form bestatin and processes for its preparation

Growing community of inventors

Tokyo, Japan

Masaaki Ishizuka